These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34767467)

  • 1. COMET - effectiveness and tolerability of methocarbamol versus oral opioid-analgesics as add-on measure in patients with non-specific low back pain refractory to recommended 1st line treatments. A retrospective analysis of depersonalized propensity score matched open-label real-world 4-week data from the German Pain e-Registry.
    Ueberall MA; Mueller-Schwefe G
    Curr Med Res Opin; 2022 Feb; 38(2):237-253. PubMed ID: 34767467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry.
    Ueberall MA; Vila Silván C; Essner U; Mueller-Schwefe GHH
    Pain Med; 2022 Apr; 23(4):745-760. PubMed ID: 34480564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of the antispasmodic, pridinol, in patients with muscle-pain - results of primepain, a retrospective analysis of open-label real-world data provided by the German pain E-registry.
    Überall MA; Müller-Schwefe GHH; Horlemann J
    Curr Med Res Opin; 2022 Jul; 38(7):1203-1217. PubMed ID: 35575167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry.
    Ueberall MA; Essner U; Vila Silván C; Mueller-Schwefe GHH
    J Pain Res; 2022; 15():267-286. PubMed ID: 35140513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Real-life efficacy and tolerability of methocarbamol in patients suffering from refractory muscle-related low/back pain - Results of a health care research project based on data from the German pain practice registry].
    Überall MA; Emrich OMD; Müller-Schwefe GHH
    MMW Fortschr Med; 2017 Dec; 159(Suppl 7):6-17. PubMed ID: 29204951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.
    Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B
    Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Painful diabetic peripheral neuropathy: real-world comparison between topical treatment with lidocaine 700 mg medicated plaster and oral treatments.
    Überall M; Bösl I; Hollanders E; Sabatschus I; Eerdekens M
    BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36368741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methocarbamol in acute low back pain. A randomized double-blind controlled study].
    Emrich OM; Milachowski KA; Strohmeier M
    MMW Fortschr Med; 2015 Jul; 157 Suppl 5():9-16. PubMed ID: 26168743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.
    Kopecky EA; Vaughn B; Lagasse S; O'Connor M
    Drugs Aging; 2017 Aug; 34(8):603-613. PubMed ID: 28600725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain.
    Friedman BW; Cisewski D; Irizarry E; Davitt M; Solorzano C; Nassery A; Pearlman S; White D; Gallagher EJ
    Ann Emerg Med; 2018 Mar; 71(3):348-356.e5. PubMed ID: 29089169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.
    Ueberall MA; Mueller-Schwefe GH
    J Pain Res; 2015; 8():459-75. PubMed ID: 26300655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Postoperative Methocarbamol and Postoperative Pain Opioid Dose Requirements: A Retrospective Cohort Study.
    Komatsu R; Singleton MD; Wu J; Dinges EM; Bollag LA
    Clin J Pain; 2023 Sep; 39(9):452-457. PubMed ID: 37284760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry.
    Ueberall MA; Essner U; Mueller-Schwefe GH
    J Pain Res; 2019; 12():1577-1604. PubMed ID: 31190969
    [No Abstract]   [Full Text] [Related]  

  • 14. Lidocaine 700 mg medicated plaster for postherpetic neuralgia: real-world data from the German Pain e-Registry.
    Überall MA; Eerdekens M; Hollanders E; Bösl I; Sabatschus I
    Pain Manag; 2022 Mar; 12(2):195-209. PubMed ID: 34372662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Tolerability of Dronabinol Use in Patients with Chronic Pain: A Retrospective Analysis of 12-Week Open-Label Real-World Data Provided by the German Pain e-Registry.
    Ueberall MA; Horlemann J; Schuermann N; Kalaba M; Ware MA
    Pain Med; 2022 Aug; 23(8):1409-1422. PubMed ID: 35104881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Effectiveness and Tolerability of Pain Treatment with Tapentadol Prolonged Release.
    Mateos RG; Bernal DS; Morera LMT; Ferri CM; Escobar AE
    Pain Physician; 2021 Jan; 24(1):E75-E85. PubMed ID: 33400440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
    Peniston JH; Gould E
    Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.